INTRODUCTION AND OBJECTIVES:
To characterize genomic aberrations of circulating, cell-free DNA (cfDNA) in bladder cancer patients treated with radical cystectomy (RC), we established a new and rapid profiling method using multiplex ligation-dependent probe amplification (MLPA). In a single reaction, MLPA allows analyzing genomic variations in 43 chromosomal regions containing 37 genes.
METHODS: We prospectively enrolled 85 bladder cancer patients treated with RC without neoadjuvant chemotherapy at our institution between 2011 and 2014. Blood samples were obtained from all patients preoperatively. Serum and plasma were prepared from 6ml whole blood in all patients. We extracted cfDNA from serum and plasma using various DNA extraction kits (QiAmp DNA Blood Mini kit, Qiagen, Hilden, Germany; QiAmp Circulating Nucleic Acid kit, Qiagen; NucleoSpin Plasma XS kit, Macherey Nagel, Dueren, Germany; PME free-circulating DNA Extraction kit, Analytik Jena, Germany). Following extraction of DNA with the applied commercial kits, we tested MLPA in serum and plasma, respectively. Eighteen probes served as references to control denaturation, ligation and amplification efficiency.
RESULTS: To identify genomic aberrations, MLPA was suitable in cfDNA extracted from serum, but not in cfDNA extracted from plasma. Serum from 72 patients (84.7%) could be analyzed. In 35 patients (48.6%), one to 6 deleted and/or amplified chromosomal regions were detected. Most changes were located in the genes E-cadherin, ZFHX3 (both amplifications in chromosome 16), RIPK2 (deletion in chromosome 8) and PTEN (deletion in chromosome 10) in 15 patients (20.8%), 12 patients (16.7%), 9 patients (12.5%) and 7 patients (9.7%), respectively. Copy number variations of various genes were associated with presence of variant histology (TSG1, RAD21, KIAA0196, ANXA7; all p-values<0.029), pathologic tumor grade (TSG1, KIAA0196, RAD21, ANXA7, TMPRSS2; all p-values<0.029), presence of incidental prostate cancer (EZH2, miR-15a, CDH1, ZFHX3; all p-values<0.024), as well as increased risk of disease recurrence (RIPK2; p¼0.038), overall (KLF5; p¼0.033) and cancer-specific mortality (KLF5, ZFHX3; all p-values<0.022).
CONCLUSIONS: In serum cfDNA, MLPA represents an efficient method for the detection of genomic aberrations among numerous chromosomal regions and genes. Copy number variations of various genes are associated with aggressive pathologic bladder cancer features and seem to have a negative impact on disease recurrence and survival. METHODS: Between 01/1994 and 04/2016, 56 patients with UraC were treated and followed at our institute. For this study, we excluded 8 patients (urothelial carcinoma). Structured work-up included at least a chest X-ray and an abdominal/pelvic CT-scan. Starting in 2001 diagnostic supra-umbilical laparoscopy (dLap) was introduced in patients with initial negative CT and revealed limited PC in 6/26 (23%) patients. Overall, staging (imaging and/or dLap) revealed 11 metastatic patients and another 9 patients, who had limited PC and were eligible for local excision of the urachus, CRS and HIPEC with open bladder. Diagnostic laparoscopy was not performed in 22/48 (46%) patients (palliative 5x; primary resection elsewhere 4x; large tumor with mucinous fluid (¼ 8cm) 3x; small, presumed benign tumor (¼ 2cm) 3x; before 2001 7x).
RESULTS: In total, 37 patients who had UraC received treatment with curative intent (28 local excision only and 9 CRS with HIPEC). Median follow-up for the 9 HIPEC patients was 33 months (IQR 59 months) and 6/9 (67%) HIPEC patients still have no signs of recurrence after median follow-up of 53 months (IQR 75 months) (see Table) . After HIPEC, two patients had postoperative adverse events requiring intervention (grade3). Disease specific survival for the patients treated with HIPEC for limited PC was comparable to the patients who had local excision only and was superior to the metastatic UraC patients (Plog-rank ¼ 0.034).
CONCLUSIONS: Laparoscopy can reliably detect limited PC in patients with UraC without radiological signs of metastasis. If limited PC is present, HIPEC represents a curative treatment with favorable oncological outcome and acceptable toxicity.
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